Table 6.
Number of NWT phenotype for different antimicrobial groups. | 2009/11 |
2013/14 |
2009/11 vs 2013/14 |
CC vs NCC |
||||
---|---|---|---|---|---|---|---|---|
CC n = 93 |
NCC n = 66 |
CC n = 117 |
NCC n = 129 |
in CC |
in NCC |
in 2009/11 |
in 2013/14 |
|
≥1 | 100% | 100% | 100% | 100% | ns | ns | ns | ns |
≥2 | 98% | 95% | 99% | 94% | ns | ns | ns | ns |
≥3 | 63% | 88% | 85% | 81% | P = 0.0004 | ns | P = 0.0006 | ns |
≥4 | 56% | 67% | 66% | 77% | ns | ns | ns | ns |
≥5 | 16% | 41% | 30% | 45% | P = 0.020 | ns | P = 0.0005 | P = 0.015 |
≥6 | 6% | 30% | 21% | 32% | P = 0.004 | ns | P = 0.00006 | P = 0.007 |
≥7 | 4% | 15% | 15% | 20% | P = 0.009 | ns | P = 0.017 | ns |
8 | 2% | 2% | 8% | 0% | ns | ns | ns | P = 0.001 |
Note: ten groups of antimicrobials were considered beta-lactams (penams and cephalosporins), macrolides, lincosamides, tetracyclines, aminoglycosides, pleuromutilins, amphenicols, fluoroquinolones and the combination of Trimethoprim/Sulfamethoxazole. Statistics performed with Pearson’s chi-squared test or Fisher’s exact test when expected frequency were lower than 5.
ns: no significant difference (p > 0.05).